Neuroprotective Effects of Guanosine in Ischemic Stroke-Small Steps towards Effective Therapy

Int J Mol Sci. 2021 Jun 27;22(13):6898. doi: 10.3390/ijms22136898.

Abstract

Guanosine (Guo) is a nucleotide metabolite that acts as a potent neuromodulator with neurotrophic and regenerative properties in neurological disorders. Under brain ischemia or trauma, Guo is released to the extracellular milieu and its concentration substantially raises. In vitro studies on brain tissue slices or cell lines subjected to ischemic conditions demonstrated that Guo counteracts destructive events that occur during ischemic conditions, e.g., glutaminergic excitotoxicity, reactive oxygen and nitrogen species production. Moreover, Guo mitigates neuroinflammation and regulates post-translational processing. Guo asserts its neuroprotective effects via interplay with adenosine receptors, potassium channels, and excitatory amino acid transporters. Subsequently, guanosine activates several prosurvival molecular pathways including PI3K/Akt (PI3K) and MEK/ERK. Due to systemic degradation, the half-life of exogenous Guo is relatively low, thus creating difficulty regarding adequate exogenous Guo distribution. Nevertheless, in vivo studies performed on ischemic stroke rodent models provide promising results presenting a sustained decrease in infarct volume, improved neurological outcome, decrease in proinflammatory events, and stimulation of neuroregeneration through the release of neurotrophic factors. In this comprehensive review, we discuss molecular signaling related to Guo protection against brain ischemia. We present recent advances, limitations, and prospects in exogenous guanosine therapy in the context of ischemic stroke.

Keywords: guanosine; neuroinflammation; neuroprotection; purinergic signaling; stroke.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers
  • Central Nervous System / drug effects
  • Central Nervous System / metabolism
  • Disease Management
  • Disease Susceptibility
  • Guanosine / pharmacology*
  • Humans
  • Ischemic Stroke / drug therapy
  • Ischemic Stroke / etiology
  • Ischemic Stroke / metabolism*
  • Ischemic Stroke / pathology
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Neuroprotective Agents / pharmacology*
  • Phosphatidylinositol 3-Kinases / metabolism
  • Protein Kinase C / metabolism
  • Signal Transduction

Substances

  • Biomarkers
  • Neuroprotective Agents
  • Guanosine
  • Protein Kinase C
  • Mitogen-Activated Protein Kinase Kinases